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Introduction
To improve 5-year survival rates for patients with colon cancer, it is critical to improve cure rates in early-stage disease (stages I-III) which account for >70% of all patients with this cancer [1] . If we only focus on patients with stage II colon cancer, who represent 25% of this group, it is still challenging for physicians to discuss the risk/benefit profile of adjuvant chemotherapy with their patients [2] .
The US National Comprehensive Cancer Network (NCCN) guidelines suggest multiple treatment options for stage II patients, ranging from observation to a variety of chemotherapy modalities [3] . Large meta-analyses and large randomized trials, e.g. the QUASAR Study, showing no-or only marginal-gain with fluoropyrimidine-based adjuvant chemotherapy if all patients with colon cancer are treated at stage II [4] [5] [6] [7] . Thus, it cannot be recommended as standard of care. Unfortunately, 15%-20% of stage II patients experience a relapse after curative surgery [8] . Therefore, there is an unmet need for molecular markers that can distinguish patients with stage II colon cancer who are highrisk for relapse.
The mismatch repair (MMR) status of the patient could serve as a basis for risk stratification. There is sufficient evidence that stage II patients with deficient MMR (dMMR) status have a lower recurrence risk and longer survival than their proficient MMR (pMMR) counterparts and do not benefit from 5-fluorouracil therapies [9] [10] [11] . The next step for a tailored molecular recurrence risk classification is to identify additional biomarkers that further separate the pMMR group into high-and low-risk patient populations. This is of particular relevance as the pMMR group constitutes 85% of stage II colon cancer patients [9] .
We previously identified the novel Metastasis Associated in Colon Cancer 1 (MACC1) gene in human colon cancer [12] . MACC1 regulates fundamental processes including cell proliferation, dissemination, epithelial-mesenchymal transition, migration, and invasion, and tumor progression and metastasis in xenograft and genetically engineered mice [12] [13] [14] [15] [16] [17] . In tumors and blood from colorectal cancer (CRC) patients, MACC1 has been shown to be a predictor for metastasis and patient survival, allowing early identification of high-risk patients [12, [18] [19] [20] [21] [22] .
Here, we analyzed MACC1 expression in the context of MMR status for patients with stage II colon cancer. We were particularly interested in the ability of MACC1 to separate patients with pMMR status into high-and low-risk groups for molecular classification in stage II colon cancer. To simplify workflow and aid clinical validation of MACC1 as a prognostic biomarker for stage II colon cancer patients, in conjunction with MMR status, particular effort was made to assess MACC1 using different technologies and independent validation cohorts.
Patients and methods
Four cohorts of CRC patients (n ¼ 596) were analyzed in this study using a variety of assays: Charité 1 discovery cohort, Charité 2 comparison cohort, BIOGRID 1 training cohort, and BIOGRID 2 validation cohort (supplementary Tables S1-S7 and Figure S1 , available at Annals of Oncology online). Full details of patient characteristic and methods (supplementary Table S8 , available at Annals of Oncology online) are given in the Appendix.
Results

Charité 1: discovery cohort
We initially evaluated MACC1 mRNA levels to aid MSI-based survival prognostication for CRC patients in the Charité 1 cohort (supplementary Table S2 , available at Annals of Oncology online). By applying the microsatellite stable (MSS)/MSI criteria (supplementary Figure S2A , available at Annals of Oncology online), MSI-high group patients had a non-significant lower probability of recurrence versus MSS/MSI-low group patients. MACC1 mRNA levels significantly stratified patients into high-and lowrisk groups based on recurrence-free survival (RFS) (P < 0.0001) (supplementary Figure S2B , available at Annals of Oncology online). The Kaplan-Meier curve for MSS/MSI-low patients separated by MACC1 mRNA level: patients with MSS/MSI-low/ MACC1-low tumors showed significantly lower probability of recurrence versus those with MSS/MSI-low/MACC1-high tumors (P < 0.01). Patients with MSS/MSI-low/MACC1-low tumors had similar RFS to those with MSI-high tumors (supplementary Figure S2C , available at Annals of Oncology online).
Charité 2: comparison cohort
The Charité 2 cohort was used to assess if, when using qRT-PCR for MACC1 mRNA detection, changing from cryo-preserved (supplementary Table S3 , available at Annals of Oncology online) to FFPE tissue samples (supplementary Table S4 , available at Annals of Oncology online) affected the results by analyzing corresponding tissue samples from the same patients.
MACC1 mRNA expression was higher in metachronously metastasizing tumors linked to higher probability of recurrence independent of the tissue type analyzed, cryo-preserved or FFPE, and of the normalization reference gene(s): MACC1 exclusively (P < 0.0001; Figure S3 , available at Annals of Oncology online).
BIOGRID 1: training cohort
Initially, we analyzed patients who did not receive adjuvant therapy. We observed significant separation of RFS between chemotherapy-naïve patients with dMMR and those with pMMR stage II T3/T4 colon cancer (P ¼ 0.03; Figure 1A ). For patients with stage II T3 disease, we also found marginal evidence of a lower recurrence probability for the dMMR versus pMMR group (P ¼ 0.08; supplementary Figure S4A , available at Annals of Oncology online).
Next, we determined MACC1 mRNA levels using qRT-PCR in chemotherapy-naïve stage II T3/T4 colon cancer patients. MACC1-high patients showed a higher recurrence probability versus MACC1-low patients ( Figure 1B ; T3 only supplementary Figure S4B , available at Annals of Oncology online).
When combining MMR status and MACC1 mRNA level in chemotherapy-naïve patients with pMMR status, MACC1-low patients demonstrated marginal evidence of a lower recurrence probability versus MACC1-high patients (P ¼ 0.09; Figure 1D ) with a 5-year RFS of 92% versus 67%, respectively (supplementary Table S5 , available at Annals of Oncology online). This observation was also made in stage II T3 patients (supplementary Figure S4D , available at Annals of Oncology online).
Of relevance, 12% (12/101) of pMMR patients had MACC1-low status, which is associated with longer survival than MACC1-high status. These pMMR/MACC1-low patients showed RFS comparable to dMMR patients with a 5-year RFS of 92% in both groups (supplementary Table S7 Kaplan-Meier Plot We also evaluated MMR and MACC1 mRNA expression in 64 patients treated with adjuvant chemotherapy. The MACC1-low phenotype was found in 16% of pMMR patients (8/49). Those patients with pMMR/MACC1-high tumors had a worse prognosis compared with pMMR/MACC1-low tumor patients ( Figure  1F ; supplementary Figure S4F , available at Annals of Oncology online).
In summary, using qRT-PCR for MACC1 detection a total of 13% of pMMR patients (20/150) in BIOGRID 1 had the pMMR/ MACC1-low phenotype and RFS similar to patients with dMMR tumors after a median follow-up of 55 months.
Next, the same tumor samples were again analyzed for MACC1 protein levels but quantified using an IHC scoring algorithm. Chemotherapy-naïve patients with 75% of cells staining for MACC1 protein expression (MACC1-high) in their primary tumors showed a trend of shorter RFS, with marginal evidence (significant at a ¼ 0.1) of higher recurrence probability versus patients with <75% of MACC1 stained cells (MACC1-low) [P ¼ 0.06 for T3/T4 tumors ( Figure 1C) ; P ¼ 0.07 for T3 tumors alone (supplementary Figure S4C , available at Annals of Oncology online)].
We analyzed the prognostic value for RFS of combined MMR status and MACC1 level in chemotherapy-naïve patients. Despite the different technology for evaluating MACC1 expression, adding MACC1 to MMR status resulted in a similar separation of the pMMR Kaplan-Meier curves: patients with pMMR/MACC1-low tumors demonstrated marginal evidence of a lower recurrence probability than patients with pMMR/MACC1-high status (P ¼ 0.07; Figure 1E ) with a 5-year RFS of 100% versus 68%, respectively. For patients with stage II T3 disease, similar trends were obtained (P ¼ 0.08; supplementary Figure S4E , available at Annals of Oncology online).
Furthermore, in the T3/T4 pMMR group, compared with patients with MACC1-high status the 8% of patients (8/101) with MACC1-low status had better RFS, which was similar to that in patients with dMMR tumors (5-year RFS of 100% and 92%, respectively, after a median follow-up of 55 months; supplementary Table S7 , available at Annals of Oncology online).
In the few chemotherapy-treated patients available for analysis, a non-significant separation of the curves was observed between the pMMR/MACC1-low and pMMR/MACC1-high groups [6% (3/49) versus 94% (46/49), respectively; Figure 1G ; supplementary Figure S4G , available at Annals of Oncology online].
In summary, using IHC to detect MACC1 protein, overall 7% of patients (11/150) with stage II pMMR tumors had the MACC1-low phenotype.
BIOGRID 2: validation cohort
To validate the identification of a pMMR/MACC1-low group with similar disease behavior as the dMMR group, the BIOGRID 2 cohort of 306 stage II colon cancer patients was analyzed by IHC using the same cutoff for MACC1-high and -low protein expression (supplementary Table S6 , available at Annals of Oncology online).
In BIOGRID 2, as in BIOGRID 1, we observed RFS separation by MMR status (Figure 2A ; supplementary Figure S5A , available at Annals of Oncology online) and by MACC1 level ( Figure 2B ; supplementary Figure S4B , available at Annals of Oncology online) in chemotherapy-naïve patients with stage II T3/T4 colon cancer. When analyzing pMMR patients by MACC1 status, the RFS curves separated further as MACC1-low versus MACC1-high ( Figure 2C ; supplementary Figure S5C , available at Annals of Oncology online) with 5-year RFS of 100% versus 90%, respectively (supplementary Table S7 , available at Annals of Oncology online). As in BIOGRID 1, we identified within the chemotherapy-naïve, pMMR subset of BIOGRID 2 a pMMR/MACC1-low group of 6% of patients (12/208) with outcomes similar to the known favorable dMMR subset.
Looking at chemotherapy-treated patients ( Figure 2D ; supplementary Figure S5D , available at Annals of Oncology online), all pMMR patients were also MACC1-high. For the pMMR/ MACC1-high population, RFS was similar to the chemotherapynaïve population, indicating a high recurrence rate despite adjuvant chemotherapy.
In summary, in BIOGRID 2, 5% of patients (12/252) had the MACC1-low phenotype. None of these patients progressed, showing a similar RFS to patients with dMMR status after a median follow-up of 44 months. Kaplan-Meier Plot 
BIOGRID 1 and BIOGRID 2: pooled
As this study was exploratory and addressed a novel marker, no estimate of effect size was available beforehand. This study was a first attempt to determine whether a potentially relevant clinical association between MMR and MACC1 expression existed. After assessment of stratification in each cohort, data from BIOGRID 1 and 2 were pooled to obtain the most precise estimate of MACC1 informative potential. This effect-size estimate is important as basis for designing future studies with sufficient power. The pooled BIOGRID chemotherapy-naïve pMMR patients were separated into high-and low-risk groups using MACC1 IHC ( Figure  2E ; supplementary Figure S5E , available at Annals of Oncology online). Of the 6.5% (20/309) of chemotherapy-naïve patients with pMMR/MACC1-low status, none experienced disease recurrence, giving an absolute difference of 17% in 5-year RFS rate versus patients with pMMR/MACC1-high status (P ¼ 0.037). The 95% confidence interval (CI) for this difference (12.6%-21.3%) supports the conclusion that pMMR/MACC1 status provides significant prognostic utility. This suggests similar outcomes for pMMR/MACC1-low patients and dMMR patients, who had a 5-year RFS of 96% (supplementary Table S7 , available at Annals of Oncology online) and might not benefit from fluoropyrimidinebased adjuvant chemotherapy.
Discussion
Management of patients with stage II colon cancer remains a challenge for oncologists. Although the adjuvant concept is well established in stage III colon cancer based on survival benefit, the effect of fluoropyrimidine-based chemotherapy for stage II patients is limited. Large, pooled analyses have not shown increased survival in the stage II colon cancer population, as the QUASAR study-the largest randomized clinical trial conducted in this population to date-did not show a survival benefit [4] [5] [6] .
New molecular biomarkers are needed to complement clinicopathological features to further distinguish risk levels in stage II colon cancers. MMR status is essential for stratification of stage II colon cancer patients [1] . Patients with dMMR stage II disease have a significantly better prognosis than patients with pMMR tumors, and do not benefit from adjuvant 5-FU chemotherapy [NCCN guidelines version 2.2017: [3] ]. Patients with pMMR T3 tumors without clinical risk factors have four different adjuvant treatment options after initial surgery: from observation only, clinical trial participation or two alternative adjuvant chemotherapies: capecitabine or 5-FU/leucovorin; patients with T3 tumors at high risk for systemic recurrence or T4 tumors have seven different options, ranging from observation, clinical trial participation to five different adjuvant therapeutic regimens: capecitabine, 5-FU/leucovorin, FOLFOX, CAPEOX, or FLOX. Consequently, treating oncologists face a dilemma as to how best to manage patients with pMMR stage II colon cancer.
Here we investigated if MACC1 expression-in conjunction with MMR status-could be a useful biomarker to further stratify pMMR stage II colon cancer patients. The MMR/MACC1 combination could be clinically relevant to either identify patients at high risk of recurrence who would potentially benefit from adjuvant chemotherapy or, conversely, to identify patients who perform clinically well without adjuvant chemotherapy. MACC1 was selected as prognostic colon cancer biomarker centrally involved in colon cancer tumor progression and metastasis [12] [13] [14] 16] . MACC1 has been established as prognostic and predictive biomarker for a variety of solid cancers such as CRC, gastric, esophageal, hepatocellular/biliary, lung, nasopharyngeal, renal, bladder, ovarian, breast and head and neck cancer, glioblastomas, osteosarcomas, including meta-analyses [23] [24] [25] [26] [27] .
We discovered MACC1 as an important transcriptional regulator of hepatocyte growth factor receptor c-Met and further genes able to induce metastasis formation and representing prognostic biomarkers for metastasis and patient survival [12, 16, 17] . MACC1 acts in different aspects of carcinogenesis, tumor progression and metastasis like gene regulation, signaling, cell proliferation, apoptosis, migration, invasion, epithelial mesenchymal translation, angiogenesis, and metabolism.
To the best of our knowledge, this is the first study analyzing a combination of MMR and MACC1 in colon cancer with a particular focus on stage II disease. Tissue samples from a cohort of 189 stage II colon cancer patients, enriched for disease recurrence, were tested for MMR and MACC1 (BIOGRID 1). MACC1 and MMR are both biomarkers with the ability to separate patients based on their RFS. Combining MACC1 as stratification marker for pMMR patients gave further prognostic separation in RFS between pMMR/MACC1-low and pMMR/MACC1-high patients with T3 or T3/T4 disease, and in patients with or without adjuvant chemotherapy. 7 and 13% of patients were identified as pMMR/MACC1-low using IHC and qRT-PCR, respectively, showing similar RFS as patients with dMMR tumors. To date, none of the pMMR/ MACC1-low patients has relapsed.
The validation cohort of 306 patients (BIOGRID 2)-in contrast to BIOGRID 1-was not enriched for patients with tumor recurrence and only MACC1 IHC was used together with MMR status. The prognostic separation of pMMR/MACC1-low and pMMR/MACC1-high was confirmed for patients with T3 or T3/ T4 tumors and for chemotherapy-naïve or -treated patients. In the BIOGRID 2 pMMR group, 5% of patients had a pMMR/ MACC1-low profile, and their RFS was similar to patients with the generally favorable dMMR status. Similar to BIOGRID 1, no tumor recurrence was observed in the pMMR/MACC1-low group after a median follow-up of 44 months.
As the sample size was not statistically derived for BIOGRID 1 or 2, no estimate of effect size was available before this study. BIOGRID 1 and 2 data were pooled to obtain the most precise estimate of MACC1's informative potential. Pooled BIOGRID 1 and 2 chemotherapy-naïve, pMMR patients significantly separated using MACC1 IHC. In pMMR patients, the 6% with pMMR/MACC1-low status did not have any recurrence events. This gave a significantly lower recurrence probability for pMMR/ MACC1-low patients, with 5-year RFS of 100% versus 81% in pMMR/MACC1-high patients. The pMMR/MACC1-low group had similar RFS to dMMR patients.
The results of the two BIOGRID cohorts and the pooled data, comprising 495 patients with stage II colon cancer, imply that MACC1 is a useful biomarker to identify the subset of 5%-7% (IHC) and 13% (qRT-PCR) of patients with pMMR/MACC1-low status, regardless of the high degree of overlap (>90%) between patients with pMMR and MACC1-high tumors. Despite the small percentage range, identification of this patient segment is clinically relevant and adds to the 15% of patients with good prognostic dMMR status, that as per NCCN V2.2017 guidelines do not benefit from 5-FU adjuvant therapy. Thus, we hypothesize that pMMR/MACC1-low stage II colon cancer patients-based on their 5-year RFS of 100%-might also derive no or marginal benefit from adjuvant chemotherapy.
Our study had several limitations: although the patient data were sourced from well-followed and well-characterized cohorts, this analysis was retrospective, used an enrichment strategy for recurrence in the BIOGRID 1 cohort to analyze the informative potential of MACC1 and MMR, and did not include patients from randomized controlled clinical trials. Furthermore, few patients were identified with pMMR/MACC1-low status by IHC (BIOGRID 1, 7%; BIOGRID 2, 5%), thus limiting the statistical power. Additional cohorts are needed to further evaluate MACC1 expression as a clinical decision-enabling biomarker in conjunction with MMR status in patients with stage II colon cancer.
In summary, we have provided evidence that the combination of MMR status and MACC1 levels has utility to identify a distinct stage II colon cancer population that has pMMR/MACC1-low status with a favorable prognosis and a RFS similar to dMMR status colon cancer patients. This finding warrants further investigation of the use of MACC1 expression for stratification of patients with stage II pMMR colon cancer in prospective clinical trials.
